NCT07420725|Active Not RecruitingDMC
The Relationship Between Gait Parameters and Balance Disorder and Fall Risk in Breast Cancer-Related Lymphedema(BCRL)
BCRL
Loading search results
BCRL
Sponsor study identifier
observational
42
1 country
1
Study Start
February 5, 2026
Actual (reported)Primary Completion
July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
In this study, researchers aimed to evaluate walking function, balance, and fall risk in patients with breast cancer-related lymphedema. The researchers' hypothesis is that balance and walking functions are affected due to a shift in the center of gravity in patients with breast cancer-related lymphedema, and that the risk of falls is increased in the patient population compared to the control group.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 4, 2026
Actual (reported)February 5, 2026
Actual (reported)February 19, 2026
Actual (reported)July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Gait analysis
The individual's walking performance will be measured using standard methods employed in clinical assessments and gait analysis studies. Measurements will be conducted in our clinic using the Zebris FDM 2 gait analysis system, and evaluations carried out with different measurement units will be reported as separate outcome criteria.
01 January 2026- 10 July 2026
The Fullerton Advanced Balance Scale (FAB-Scale)
The FAB Scale is a performance-based test that assesses functional balance (static and dynamic). Functional balance includes static and dynamic components such as the body's overall balance ability, muscle coordination, proprioception, range of motion, muscle strength, and flexibility.
01 January 2026- 10 July 2026
Modified Fall Effectiveness Scale (MFES)
The MFES is a self-report scale used to assess individuals' levels of fear of falling while performing various daily life activities. An adaptation of the Tinetti Fall Activity Scale (FES), the MFES aims to improve cultural adaptability by more comprehensively evaluating social and environmental factors.
01 January 2026- 10 July 2026
Quick-DASH (Q-DASH)
The Q-DASH consists of 11 items derived from the DASH questionnaire to measure physical function and symptoms of the upper extremity. This index assesses the difficulties patients have experienced in daily living activities over the past week using a 5-point Likert scale. At least 10 out of 11 items must be answered to calculate the Q-DASH score. All items in the questionnaire are scored between 1 and 5. A score of 1 indicates no difficulty during the activity, while a score of 5 indicates complete inability to perform the activity. The Q-DASH has been found to be valid and reliable for assessing upper extremity activity limitations in breast cancer patients.
01 ocak 2026- 10 temmuz 2026
LYMQO-Arm Index
The LYMQOL Arm Index is a tool that measures the impact of lymphedema on arm function and assesses its effects on quality of life. It measures the effects on arm function, psychological health, social interactions, and physical symptoms. The index allows monitoring of arm swelling, pain, limitations in movement, and the impact of these effects on psychological and social life.
01 January 2026- 10 July 2026
Female patients aged 18-65 years who are evaluated for upper extremity swelling after breast cancer surgery and/or radiation therapy and diagnosed with BRCL
Patient group aged 18-65 and age and gender-matched healthy female control group.
Female patients aged 18-65 years who presented to the Lymphedema outpatient clinic of the Physical Medicine and Rehabilitation Department at Kayseri City Hospital with upper extremity swelling following breast cancer surgery and/or radiation therapy and were diagnosed with BRCL (Group 1: LG, lymphedema group) will be included in the study. The control group (Group 2: KG) will consist of age- and gender-matched volunteer participants who presented to the Physical Medicine and Rehabilitation outpatient clinics with non-specific pain complaints and who did not have any postural, neurological, or orthopedic disorders.
Kayseri City Hospital
Kayseri, Turkey (Türkiye)
Fatma G Ülkü Demir, baş araştırmacı
Kayseri City Hospital
First Submitted
February 4, 2026
First Posted
February 19, 2026
Study Start
February 5, 2026
Actual (reported)Primary Completion
July 10, 2026
Estimated (date passed)The Effect of Mobile Lymphedema Self-Care Support Program on Self-Care in Women With Breast Cancer-related Lymphedema
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 9, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: